[Skip to Content]

Upstate Active Clinical Trials

Study Title:

ECOG E4512 - A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

What is the purpose of the study?

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Tumors with this mutation may respond to treatments that target the mutation, such as crizotinib. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. It is not yet known if crizotinib may be an effective treatment for treating non-small cell lung cancer with an ALK fusion mutation.

Upstate Institutional Review Board (IRB) Number:

659082

Study/Protocol ID:

E4512

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

Where will the study take place?

Upstate Cancer Center-All procedures
Oneida-All procedures
Oswego-All procedures

ClinicalTrials.Gov ID:

NCT02201992

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Erinn Mcdowell, MS, CCRP
Phone: 315-464-8230
Email: mcdowele@upstate.edu

Return to Previous Page || Search Again

Top